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Abstract 
Background: Latent autoimmune diabetes in adults (LADA) accounts for  11 % of all cases of 
diabetes and often misdiagnosed as type 2diabetes. LADA resembles type 1diabetes and shares 
common physiological characteristics of type 1 but it does not affect children and has been 
classified distinctly as being separate from juvenile diabetes. Autoantibodies against glutamic acid 
decarboxylase 65 (GADA) and tyrosine phosphatase (IA-2) are found frequently in patients with 
LADA. The presence of these autoantibodies in LADA predicts inevitable β cell failure and poor 
response to oral hypoglycemic therapy i.e., patients with LADA do not respond to oral 
hypoglycemic therapy. 
Objective: To determine an immunological marker to diagnose patients not responding to oral 
hypoglycemic therapy.  
Patients and methods: A facility-based cross sectional study was conducted in Jabbir Abu Eliz 
Diabetes Center, located at Khartoum 2. Venous blood samples were obtained from the study 
patients. They were divided into three groups, group1 included 27 diabetic patients treated with 
insulin, group2 included 15 diabetic patients of type 2 diabetes as controls, and group3 included 15 
newly diagnosed patients older than 35 years at onset of diabetes. A standardized pre-tested 
administered questionnaire was used for data collection and the collected data were analyzed. 
Results: Males encountered in the study were 28 (49.1%). On patient recently diagnosed to have 
type 2 diabetes mellitus (T2DM) was positive for autoantibodies to GDA/IA-2. These 
autoantibodies were also positive in 15 patients with diabetes mellitus type 1 (T1DM) 
Conclusions: Autoimmune diagnostics is of particular importance in adults to discriminate between 
type 1 and type 2 diabetes and to assess the diagnosis of latent autoimmune diabetes in adults. The 
current study results revealed that autoantibodies to GAD/IA-2 are good marker for diagnosis of 
latent onset DM type 1. On the other hand, data indicate that the vast majority of cases of type 1 
diabetes may be considered as immune-mediated, that multiple autoantibody to GAD/IA-2 analysis 
are of prognostic value to predict complications e.g., retinopathy. The current study recommends 
using of anti-GAD/IA-2 antibodies as marker for diagnosis of latent autoimmune diabetes in adults 
(LADA) who are not responding to oral hypoglycemic and may be at risk for getting complications. 
On the other hand, the study recommends using of anti-GAD/IA-2 antibodies for prognosis of the 
clinical progression of diabetes type 1 for prediction of insulin dependence. 
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n 1977 Irvine and others1 reported that 
11% of patients with type 2 diabetes were 
positive for Islet Cell Autoantibodies 
(ICA) and that this ICA subset of type 2 
diabetic patients tended to fail sulfonylurea 
therapy and needed insulin treatment. 
The type of diabetes in these patients was 
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referred to as slowly progressive IDDM, 
latent type 1 diabetes, youth-onset diabetes of 
maturity, latent-onset type 1 diabetes, 
antibody-positive non-insulin-dependent 
diabetes and latent autoimmune diabetes in 
adults(LADA)2,3,4. The term LADA has been 
used to describe adult onset subjects who 
develop a phenotypic type 2 diabetes 
(T2DM), but with the presence of beta cell-
specific autoantibodies (glutamic acid 
decarboxylase 65 (GADA), insulinoma- 
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antigen 2 (IA-2A) and with a slower 
progression to beta cell failure compared to 
classical type 1 diabetes5-7.
Glutamic acid decarboxylase autoantibodies 
(GAD-Abs), which is present in the 
cytoplasm of the human β-cell, is an enzyme 
required for γ-aminobutyric acid (GABA) 
synthesis that acts as neurotransmitter in 
neurons of central nervous system, in 
pancreatic islets8 and probably involved in 
controlling the release of insulin from 
secretary granules. Autoantibodies to 
Glutamic Acid Decarboxylase 65 antibodies 
(GAD65) show no correlation with age at 
onset and are therefore particularly attractive 
markers for autoimmune diabetes in the adult 
population9. Moreover, GAD65Ab can be 
detected years after the clinical onset of the 
disease, indicating that these autoantibodies 
may be permanent markers for the 
autoimmune response10. However, it has been 
suggested that antibodies to antigens other 
than GAD and IA-2 are more prevalent in 
LADA11 and raise the intriguing possibility 
that some unidentified antigens are more 
commonly involved in LADA than type 1 
diabetes. 
Patients with type 1 DM retinopathy have 
shown inverse correlation to GAD65Ab12.
GADA may have some effect on the 
development of diabetic retinopathy since 
GAD65 is expressed in the neural retina as 
well as the pancreas and the central nervous 
system13,14,15 and were associated with an 
increased risk of diabetic retinopathy 15 years 
later16.
The aim of this study was to determine an 
immunological marker to diagnose missed 
cases of LADA among Sudanese patients not 
responding to oral hypoglycemic therapy. On 
the other hand, the study measured levels of 
autoantibodies to GAD 65 and IA-2 in 
patients with diabetes mellitus type 1 to 
predict patients at risk of diabetic retinopathy.  
Materials and methods: 
Ethical consideration: An ethical clearance 
was obtained from the authorities of Jabbir 
Abu Eliz Diabetes Center. Informed consents 
were obtained from the study patients before 
interviewing and the aims and procedures of 
the study were explained clearly to all 
patients.  
Study design: facility-based cross sectional 
study. 
Study setting:  
Jabbir Abu Eliz Diabetes Center is composed 
of many departments to provide care of 
diabetic patients in all ages.  
Study population: 
Diabetic patients of both genders of various 
age groups and different ethnic groups who 
were regularly attending the referral diabetic 
clinics, were enrolled in the study. Patients 
were divided into 3 groups; group1 included 
27 diabetic patients treated with insulin, 
group2 included 15 diabetic patients of type 2 
diabetes as controls, and group3 included 15 
newly diagnosed patients older than 35 years 
at onset of diabetes.  
Data collection: 
A standardized pre-tested administered 
questionnaire was used for data collection. 
The questionnaire was composed of close-
ended questions covering personal 
characteristics, history of diabetes, duration of 
diabetes mellitus, family history of diabetes, 
history of other illnesses, treatment 
modulation, duration of treatment and result 
of fasting blood glucose.   
Sample processing:Five ml of blood 
collected from each patient was left to clot for 
2-3 hour at room temperature and then 
centrifuged at 3000 rpm for 10 minutes and 
serum was stored at minus 20oC until use.  
Measurement of fasting blood glucose 
level:Glucose  level was  measured  
immediately before  blood  clotting  by using  
Trinder’s  glucose  oxidase  method. In brief, 
glucose was essentially oxidized to gluconic 
acid and hydrogen peroxide by glucose 
oxidase. The hydrogen peroxide produced 
was reacted in the presence of peroxidase 
with 4–aminoantipyrine and 
p.hydroxybenzene sulphonate to form 
aquinonimine dye. The intensity of the colour 
produced was measured at 505 nm. Glucose 
concentration was calculated according to the 
following formula: 
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Glucose concentration of samples in mg/dl =  
 A sample – A blank X concentration of standard in mg / dl 
 A standard – A blank 
 
Detection of autoantibodies using Enzyme 
Linked Immuno-Sorbent Assay (sandwich 
ELISA): 
The frozen samples were prepared by 
transferred to room temperature (RT). Sixty-
five wells plate (six wells for calibrators from 
1 to 6, one well for negative controls, and one 
for positive control and 57 wells for samples) 
from ELISA plate (Euroimmun) coated with 
anti-GAD/IA2 pool was used.  Fifty µl of
each sample, calibrators and control were 
added to the wells, and then 25 µl of sample 
buffer was added to each well. The plate was 
covered and shacked for five seconds at 500 
rpm, and incubated for 18 hours at 4oC to 8oC
and then washed 3X using washing buffer. 
Following that, 100µl of GAD/IA2 (biotin-
labelled GAD and IA2) was added and the 
plate incubated for 1 hour at RT on 
microplate shaker set at 500 rpm. After the 
second wash, 100 µl of enzyme conjugate 
(peroxidise-labelled avidin) was added to 
each well, covered and then incubated for 20 
minutes at RT on shaker set at 500 rpm. Then 
washed 3X by washing buffer. In the final 
step, 100 µl of chromgen/substrate solution 
was added to each well, incubated for 20 
minutes at RT, away from direct sunlight 
contact, and then  100 µl of stop solution was 
added to each well. The intensity of the 
colour was read at wave length of 450 nm. A 
value of 4 IU/ml was considered positive. 
Statistical analysis:  
The samples were analyzed using SPSS 




The 57 participants consisted of 28 (49.1%) 
men and 29 (50.9%) females. Among these, 
27 of type 1 DM, 15 diabetic patients of type 
2 diabetes (control group) and 15 newly 
diagnosed patients older than 35 years at 
onset of diabetes (type 2 DM).  
As shown by table 1 that the age of onset of 
diabetes in controls and in newly diagnosed 
patients was between 25 and 35 years of age. 
As shown in table 2, autoantibodies to 
GAD/IA-2 were detected in 26.3% (15/27) of 
type 1 diabetes, on the other hand only one of 
15 (1.8%) who had been diagnosed recently 
as type 2 DM (>35 years old) was positive for 
anti GAD/IA-2 (i.e., LADA), and that patient 
was on oral hypoglycemic therapy (table 3) 
 
Table1-: Age distribution of the study population 
 
Age (in years)  T1 DM No. (%) T2DM* No. (%) T2DMΨ No. (%) Total 
< 15 3 (5.3%)  - - 3 (5.3%) 
15 – 24  16  (28.7%)  - - 16 (28.1%)  
25 – 34 8 (14.0%)  8 (14.0%)  - 16 (28.1%)  
> 35 - 7 (12.3%)  15 (26.3%)  22 (38.6%) 
Total  27 (47.4%)  15 (26.3%)  15 (26.3%)  57 (100%) 
* T2DM* (control group).                                                     T2DMΨ (newly diagnosed) 
 
Table 2-: Autoantibodies to GAD/IA-2 pool in study population 
ELISA test for 
GAD/IA-2 
T1 DM No. (%) T2DM* No. (%) T2DMΨ No. (%) Total 
Negative 12 (21.1%)  15 (26.3%)  14 (24.6%) 41 (71.9%) 
Positive  15 (26.3%)  - 1 (1.8%) 16 (28.1%) 
Total  27 (47.4%)  15 (26.3%)  15 (26.3%)  57 (100%) 
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Table 3-: Relation between the type of treatment and the positive result of GAD/IA-2 pool 
 
Groups   Type of treatment  ELISA test for GAD/IA-2 Total 
Negative  Positive  
Type I Diet  3 (11.1%) - 3 (11.1%)  
Oral hypoglycaemia  1 (3.7%) 1 (3.7%) 2 (7.4%)  
Insulin  7 (25.9%)  13 (48.1%) 20 (74.1%) 
Combination  1 (3.7%)  1 (3.7%)  2 (7.4%)  
Total  12 (44.4%) 15 (55.6%) 27 (100.0%)  
T2DMΨ Oral hypoglycaemia  11 (73.3%) 1 (6.7%) LADA 12 (80.0%)  
Insulin  2 (13.3%)  - 2 (13.3%)  
Combination  1 (6.7%) - 1 (6.7%) 
Total  14 (93.3%) 1 (6.7%) 15 (100.0%) 




No. (%) of 
positive patients 
for GAD/IA-2 
Mean ± SD 
FBS result   
Mean ± SD for 
GAD/IA-2 
Concentration  
No. (%) with DKA 
history  
Yes  No 
Total  16 (28%)  160.38± 81.47 49.256± 58.288 11 (68.8%)  5 (31.3%) 
P. value   0.44 0.64   
* Stander deviation (± SD) 
 
In addition, we found no significant 
correlation between GAD/IA-2 
concentrations and the complication e.g., 
diabetic ketoacidosis history (DKA) (p <0.64) 
(table 4). 
Type 1 diabetic when compared with control 
group (type2), there was significant difference 
(P<0.007) in the concentration of GAD/IA-2 
positive subject, likewise when compared 
with newly diagnosed type 2 diabetic patients 
a significant difference (P<0.008) was also 
found.  
Discussion: 
This is the first study to describe the presence 
of autoantibodies to GAD/IA-2 in patients 
with diabetes mellitus type 2 who are not 
responding to oral hypoglycaemic therapy. 
On the other hand the current study is the first 
to measure levels of these autoantibodies in 
patients with diabetes mellitus type 1 to 
predict patients at risk of diabetic retinopathy. 
 Males encountered in the study were 
28 (49.1%) cases while females were 29 
(50.9%) cases. 27 of them were suffering  
 
from type 1DM and 15 were diagnosed as 
type 2 DM (control group). The remaining 15  
individuals were newly diagnosed as having 
type 2 DM and were above 35 years of age at 
onset of diabetes. The presence of 
autoantibodies to GAD/IA-2 in one individual 
(1.8%) with late onset DM and in 15 out of 27 
(26%) patients with classic childhood type 1 
diabetes supports the evidence that the 
underlying disease process in both patient 
groups is autoimmune. The findings by the 
current study were in agreement with study 
conducted by Torn and others17 who reported 
that a higher percentage [80% (135/169)] of 
patients positive for anti GAD65/IA-2 were 
found in patients with type 1 DM in South 
Indian and Australia. In addition, it was in 
accordance with a finding by Abigail and 
others18 who found that around 2.6% (13/500) 
of individuals were LADA patients.  
The Immunology Diabetes Society has 
recently proposed the following criteria for 
diagnosis of patients with LADA: patients 
should be at least 30 years of age, positive for  
at least one of the four antibodies commonly  
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found in type 1 diabetic patients (ICAs and 
autoantibodies to GAD65, IA-2, and insulin), 
and not treated with insulin within the first 6 
months after diagnosis. Accordingly, the 
current study results indicate that 
autoantibodies to GAD65 and IA-2 are good 
marker for diagnosis of LADA and this has 
also been shown by Engl and others in U.S.A 
who stated that GAD65/IA-2 test has clinical 
significance for diagnosis of LADA19.
The results show that there was no 
significant correlation between anti GDA/IA-
2 concentration and history of diabetic 
ketoacidosis (p < 0.64). This finding is in 
agreement with a recent study in adult 
European diabetes patients that has shown 
that metabolic syndrome is not more 
prevalent in patients with autoimmune 
diabetes than in control subjects i.e., 
metabolic syndrome is not a characteristic of 
autoimmune diabetes20.
Fifteen patients with type 1 DM were positive 
for GAD65/IA-2 pool. Since GAD65 
autoantibodies are detected against glutamic 
acid decarboxylase (GAD), which is mainly 
expressed in islets and nervous tissue in type 
1 diabetic patients, GAD65A autoantibodies 
might be associated with retinopathy in these 
patients12. Accordingly, testing for these 
autoantibodies has a prognostic value for the 
severity of the disease in patients with type 1 
DM. Thus; the current study recommends 
measuring autoantibodies to GAD 65 in all 
individuals with suspected retinopathy, and 
should be a part of routine investigations to 




Data indicate that the vast majority of cases of 
type 1diabetes may be considered as immune-
mediated, that multiple autoantibody analysis 
improves identification of the disease, and 
that screening is provided by the combined 
detection of autoantibodies to GAD/IA-2. 
Autoimmune diagnostics is of particular 
importance in adults to discriminate between 
type 1 and type 2 diabetes and to assess the 
diagnosis of latent autoimmune diabetes in 
adults. Using of autoantibodies to GAD/IA-2 
as diagnostic and prognostic marker for 
diagnosis of latent autoimmune diabetes in 
adult (LADA) who are not responding to oral 
hypoglycemic and may be at risk for getting 
complications and on the other hand for 
prognosis of the clinical progression of 
diabetes type 1 for prediction of insulin 
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